U.S. markets closed

Affimed N.V. (AFMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.8500+0.0400 (+1.05%)
At close: 4:00PM EDT

4.0200 +0.17 (4.42%)
After hours: 7:51PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close3.8100
Open3.8500
Bid3.8500 x 3200
Ask3.8300 x 3200
Day's Range3.8000 - 3.9800
52 Week Range1.4200 - 4.9100
Volume3,053,595
Avg. Volume1,609,155
Market Cap293.562M
Beta (5Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)-0.7170
Earnings DateAug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.06
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Earnings Outlook For Affimed

    Affimed (NASDAQ: AFMD) releases its next round of earnings this Tuesday, August 11. Here's Benzinga's essential guide to Affimed's Q2 earnings report.Earnings and Revenue Affimed EPS will likely be near $-0.16 while revenue will be around $5.57 million, according to analysts. In the same quarter last year, Affimed reported EPS of $-0.19 on revenue of $4.49 million. The Wall Street estimate would represent a 15.79% increase in the company's earnings. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate -0.14 -0.19 -0.17 -0.14 EPS Actual -0.12 -0.21 -0.19 -0.19 Revenue Estimate 5.93 M 2.94 M 4.45 M 3.97 M Revenue Actual 5.66 M 4.33 M 2.29 M 4.49 M Stock Performance Over the last 52-week period, shares are up 37.87%. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release.View more earnings on AFMDDon't be surprised to see the stock move on comments made during its conference call. Affimed is scheduled to hold the call at 08:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/zk8ceyktSee more from Benzinga * Stocks That Hit 52-Week Highs On Thursday * Stocks That Hit 52-Week Highs On Friday * Morning Market Stats in 5 Minutes(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Affimed Announces Two New Appointments to Its Supervisory Board

    Heidelberg, Germany, August 5, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointments of Dr. Annalisa Jenkins and Mr. Harry Welten to its Supervisory Board.  Both these appointments were approved during the Annual General Meeting of Shareholders which took place on August 4, 2020.“Affimed is pleased to welcome Annalisa and Harry, both highly experienced professionals in their respective fields, to the Supervisory Board” said Dr. Thomas Hecht, Chairman of Affimed’s Supervisory Board. “Annalisa is a visionary leader who knows how to translate science from bench to bedside.  Harry is an accomplished financial executive who is well suited to help drive value-creating strategies for the company.  Together, these new appointments position us to ensure sound corporate governance by further strengthening our biotech industry know-how and experience as well as our diversity.”Dr. Jenkins, with more than 25 years of global pharmaceutical experience, brings a wealth of expertise in advancing clinical programs through development and to regulatory approval. Dr. Jenkins serves on the Board of Directors for a number of publicly and privately held biotechnology and life science companies. In addition, she is a committee member of the science board to the U.S. Food and Drug Administration (FDA), which advises FDA leadership on complex scientific and technical issues.  Dr. Jenkins served as the Chief Executive Officer of PlaqueTec Ltd. and Dimension Therapeutics. Prior leadership roles held by Dr. Jenkins include Executive Vice President, Global Research and Development­ at Merck Serono Pharmaceuticals as well as several leadership positions at Bristol-Myers Squibb. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital at the University of London and subsequently trained in cardiovascular medicine in the UK National Health Service.Mr. Welten brings significant financial and U.S. market expertise to Affimed.  He is chairman and member of the board of directors of several biotechnology companies in Switzerland, Germany and the U.S.  Over the last 20 years, Mr. Welten served as Chief Financial Officer of both public as well as venture capital financed biotech companies. Mr. Welten has served in senior roles at UBS in Switzerland and New York for the first 15 years of his career. Mr. Welten has degrees in Banking, Finance and Economics as well as an MBA from Columbia University, NY, USA.About Affimed N.V. Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of AFM24, the value of our ROCK® platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation and the risks, uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.Investor ContactAlex FudukidisHead of Investor RelationsEmail:  IR@affimed.comTel: (917) 436-8102

  • GlobeNewswire

    Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020

    Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2020 results on Tuesday, August 11, 2020 and host a conference call at 8:30 a.m. EDT to discuss financial results and corporate developments. The conference call will be available via phone and webcast. To access the first quarter results call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 8855368 approximately 15 minutes prior to the call.To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.About Affimed N.V.Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.Investor & Media Contact:Alex Fudukidis Head of Investor Relations E-Mail: a.fudukidis@affimed.com Tel: (917) 436-8102